It was also discovered that HER2-positive BC patients with a serum HER2 ECD of more than 15 ng/mL [37,38], a greater carbonic anhydrase (CAIX) [38], or metalloproteinases [39] had shorter progression-free survival (PFS). The gene discussed is ERBB2; the disease is breast cancer.